Ctrl

K

Olezarsen

Class
Hypolipidemic agents
Subclass
Apolipoprotein C-III-directed antisense oligonucleotides
Substance name
Olezarsen
Brand names
Tryngolza®
Common formulations
Solution for injection
Indications for use
Labeled indications
Adults
Treatment of familial chylomicronemia syndrome
Safety risks
Contraindications
Hypersensitivity to olezarsen or its components
Warnings and precautions
Drug hypersensitivity reaction
Maintain a high level of suspicion, as hypersensitivity reactions, including bronchospasm, diffuse erythema, facial edema, urticaria, chills, and myalgias, have been reported with olezarsen.
Specific populations
Renal impairment
eGFR ≥ 30 mL/min/1.73 m²
Use acceptable. No dose adjustment required.
eGFR < 30 mL/min/1.73 m²
No guidance available.
Renal replacement therapy
Any modality
No guidance available.
Hepatic impairment
Child-Pugh A (mild)
Use acceptable. No dose adjustment required.
Child-Pugh B (moderate)
No guidance available.
Child-Pugh C (severe)
No guidance available.
Pregnancy and breastfeeding
Pregnancy
All trimesters
Insufficient evidence. Severe gestational hypertriglyceridemia may occur during pregnancy in patients with familial chylomicronemia syndrome, increasing the risk of acute pancreatitis.
Breastfeeding
Use only if benefits outweigh potential risks.
Unknown amount excreted in breastmilk.
Unknown drug levels in breastfed infants.
Unlikely to cause adverse effects in breastfed infants.
Adverse reactions
Very common > 10%
↓ platelet count, injection site reactions
Common 1-10%
Arthralgia
Unknown frequency
↑ blood glucose, ↑ HbA1c, ↑ liver enzymes, ↑ serum LDL, ↑ serum ApoB, bronchospasm, facial edema, skin erythema, urticaria, chills, myalgia
Interactions
Drug(s)
Check Interactions
Reset

What did you think about this content?

Create free account

Sign up for free to access the full drug resource